The Clero Stem Cell Treatment Center we exploit anti- inflammatory, immuno-modulatory and regenerative properties of adult stem cells to mitigate inflammatory and degenerative diseases.
The Clero Stem Cell Treatment Center offers protocols and investigational use of Autologous Adult Adipose Derived Stem Cells (ADSC's) for clinical research and deployment for numerous Autoimmune disorders, inclusive of:
These ADSC's cells are derived from fat - an exceptionally abundant source of stem cells - that has been removed during our mini-liposuction office procedure. The source of the regenerative stem cells actually comes from stromal vascular fraction (SVF) - a protein rich segment from processed adipose tissue. Stromal vascular fraction contains a mononuclear cell line (predominantly autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important growth factors that facilitate the stem cell process and promote their activity. Our technology allows us to isolate high numbers of viable cells that we can deploy during the same surgical setting.
The SVF - stem cell fraction are harvested, concentrated, then deployed back into the patient's body via injection or intravenous infusion on an outpatient basis (often times both methods are used). The total procedure takes less than 4 hours. Not all Autoimmune disorders respond to stem cell therapy, and each patient must be assessed individually to determine the potential for optimal results from this regenerative medicine process.
The Clero Stem Cell Treatment Center, is committed not only to providing a high degree of quality care for our patients - but we are also highly committed to clinical stem cell research and the advancement of regenerative medicine.
Rheumatoid arthritis is an autoimmune inflammatory disease that affects 1.3 million Americans. Rheumatoid Arthritis is a condition marked by inflammation in the joints; it is an autoimmune disease common in middle age, especially in women. Immune cells invade joints secreting cytokines that cause swelling and pain. The chronic inflammatory process causes thickening of the synovium with eventual loss of joint mobility. The immune system attacks the joints, resulting in inflammation, irritation, and cartilage damage. Rheumatoid arthritis usually occurs in joints on both sides of the body. Common sites of swelling, pain, and redness include the hands, wrists, and knees, but other joints and organs may be affected.
Early aggressive therapy with immunosuppressive drugs and anti- inflammatories appears to delay joint destruction. More recently, biologic agents have been added to regimens that include TNF inhibitors, WBC modulators, and growth factor inhibitors.
Although treatments are aimed at quelling inflammation and halting disease process, new regenerative medicine approaches are also being explored. Research is ongoing to evaluate the effects of stem cells on auto-immune conditions. According to the Journal of Translational Research, "The ability of MSC to inhibit immune response, while offering the possibility of inducing/accelerating healing of tissue that has already been damaged, makes this population attractive for treatment of autoimmune disorders." Journal of Translational Medicine 2009, 7:29 doi: 10.1186/1479-5876-7-29.
The Clero Stem Cell Treatment Center has developed and adopted a rheumatoid arthritis protocol that utilizes the anti-inflammatory and immune-modulating properties of adult stem cells.
Lupus (systemic lupus erythematosus or SLE), an autoimmune disease, considered a collection of diseases, in which the immune system attacks healthy tissues, especially in the joints (especially fingers, wrists, hands, and knees). In this and related conditions, the immune system mistakenly attacks healthy tissues, leading to inflammation, pain, swelling, and tissue destruction. Most patients with SLE experience symptoms in the joints of the hands, fingers, wrists, and knees. Patients often develop fatigue, rash, fever, and swollen lymph nodes; many body parts can be affected.
As with other auto-immune conditions, anti-inflammatory medications and immune-suppressants are used commonly for treatment; but there is no known cure. Sometimes cytotoxic drugs are used for severe cases. Research is also ongoing to evaluate the effects of stem cells on auto-immune conditions. Cutting-edge approaches are being studied. The Clero Stem Cell Treatment Center, along with the California Stem Cell Treatment Center has developed and adopted a lupus protocol that utilizes the anti- inflammatory and immune-modulating properties of adult stem cells.
Myasthenia gravis (MG) is an autoimmune neuromuscular disease leading to fluctuating muscle weakness and fatigability. It is an autoimmune disorder, in which weakness is caused by circulating antibodies that inhibit the excitatory effects of the neurotransmitter acetylcholine on neuromuscular junctions. Muscular fatigue is often seen and MG is associated with ocular problems, and speech, swallowing, and breathing can be affected.
Myasthenia Gravis is treated medically with acetylcholinesterase inhibitors or immunosuppressants, and in selected cases, thymectomy. MG is associated with other auto-immune conditions, including thyroid disease, lupus, and diabetes. Animal model studies are ongoing and, according to the Scandinavian Journal of Immunology in 2010, a study demonstrated that hMSC (mesenchymal stem cells) treatment was therapeutically useful in autoimmune myasthenia gravis mice, and the underlying mechanism may relate with their immunomodulatory potential (Scand J. Immunol., 2010 Sep;72(3):242-9. doi: 10.1111/j. 1365-3083.2010.02445.x. Intravenous administration of bone marrow mesenchymal stem cells benefits experimental autoimmune myasthenia gravis mice through an immunomodulatory action. Yu J, Zheng C, Ren X, Li J, Liu M, Zhang L, Liang L, Du W, Han ZC, from the State Key Laboratory of Experimental Hematology,
While human research is ongoing to evaluate the effects of stem cells on auto-immune conditions, the Clero Stem Cell Treatment Center, has developed a specific SVF deployment protocol that attempts to utilize the potential immune-modulatory and regenerative properties of SVF (rich in mesenchymal stem cells and growth factors) to mitigate symptoms of Myasthenia Gravis.
Hepatitis is characterized by inflammation of the liver. In some people, the underlying cause is an autoimmune attack in which the immune system destroys the body's own tissues. (These individuals may also be dealing with other autoimmune diseases.) Auto- immune hepatitis is an inflammatory auto-immune disease of the liver. It often occurs with other auto-immune conditions such as scleroderma, lupus, Crohn's, and Graves thyroid disease. Patients experience fatigue, loss of appetite, itching, and abdominal distension. Treatment with corticosteroids is the standard of care, but the hepatitis may cause cirrhosis (scarring) and eventually lead to liver failure.
The primary cause of hepatitis, however, is viral infection (hepatitis A, B, and C) . Other common causes include excessive use of alcohol, overdoses of acetaminophen and other medications, and bacterial infections. Whatever the cause, it is important to arrest the progression of hepatitis. If left untreated, it may progress to cirrhosis, liver cancer, and complete liver failure.
The Clero Stem Cell Treatment Center has developed a specific SVF deployment protocol that attempts to utilize the potential immune-modulatory and regenerative properties of SVF (rich in mesenchymal stem cells and growth factors) to mitigate symptoms of auto-immune hepatitis.
Crohn's disease is a type of inflammatory bowel disease that occurs in 500,0000 people in North America. It may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms, including abdominal pain, bloating, diarrhea, bloody diarrhea, vomiting and weight loss. Skin rashes and arthritis also occur. Although there is a genetic component to Crohn's disease, it is an auto-immune disease in which the person's own immune system attacks the gastrointestinal tract. The terminal ileum is the part of the bowel most often affected in this disease.
Treatment often includes immune-suppressant therapy with steroids. Antibiotics and anti-inflammatories are also used extensively. In Europe, stem cells are used commonly to treat Crohn's. Research is ongoing to evaluate the effects of stem cells on auto-immune conditions. The Journal of Translational Research reports that "non-expanded SVF cells have been used successfully in accelerating healing of Crohn's fistulas."
Further, as reported in Science Daily: "Clinical Trial Success for Crohn's Disease Cell Therapy," cell therapy is quite promising as a treatment adjunct in Crohn's Disease. Biotechnology and Biological Sciences Research Council (2011, March 31). Clinical trial success for Crohn's disease cell therapy. ScienceDaily.
©2015 La Clinique de France Internationale, All Rights Reserved
Powered by: Raysag Design